Case Reports

Woman With Post-Partum Kidney and Liver Failure
Joshua Gibbs MD, PGY-3

The patient is a 34 year-old G1P1 Caucasian female with
no medical history who was transferred from an outside
hospital after an emergent Cesarean section for increasing
jaundice with elevated liver enzymes, abnormal
coagulation times and acute renal failure. The patient
was healthy until 33 weeks gestation when she noted
dizziness, headache and visual changes. Blood pressure at
that time was elevated at 140/90 and she had trace lower
extremity edema. No proteinuria was detected. The
clinical picture was consistent with mild pre-eclampsia.
The patient was followed until 35 weeks gestation when
she developed vaginal bleeding and abdominal pain. At
that time, an emergency C-section was performed due
to a non-reassuring fetal heart rate. On the first night
after the surgery, she became anuric and laboratory tests
demonstrated acute renal failure, coagulopathy, and
elevated liver enzymes. She became progressively
jaundiced and she was transferred for further
management. On admission, she complained of nausea
and malaise. She denied abdominal pain, chest pain,
dyspnea, lightheadedness or headache.
Her past medical history was only significant for
endometriosis. Her past surgical history included
laparoscopic treatment of endometriosis several years ago
and ovarian cyst removal several years ago. Her
medications included Phenergan, Percocet, Lasix and
Dulcolax. She had allergies to Augmentin and Ceclor
which caused a rash. Her family history was noncontributory. The patient noted occasional tobacco use,
denied alcohol or other substances. Her review of systems
was only significant for mild dyspnea, nausea, mild
gingival bleeding, and mild pruritis.
Vital signs showed a temperature of 99.0F, pulse of 84
beats per minute, respirations of 22 breaths per minute,
blood pressure of 130/70 with blood oxygenation at 99%
on room air. Her physical examination was significant for
scleral icterus; her heart rate was regular without murmurs,
rubs or gallops; her lungs had bibasilar crackles; her
abdomen was soft with some tenderness at her incision
site with minimal oozing; she had moderate lochia and
was heme negative rectally; she had 2+ pitting edema on
her bilateral lower extremities; neurologic examination was
intact with some asterixis noted.
Her laboratory findings on admission were significant for
a sodium of 122mg/dL, potassium of 5.2mmol/L,
bicarbonate of 17mmol/L, BUN of 33mg/dL, creatinine
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of 3.3 mg/dL, PTT of 55.6 sec, PT of 23 sec, INR of 2.5,
fibrinogen of 94mg/dL, protein of 3.9g/dL, albumin of
2.0g/dL, total bilirubin of 9.7mg/dL, direct bilirubin of
5.4mg/dL, AST of 124mg/dL, ALT of 104mg/dL, alkaline
phosphatate of 390U/L, ammonia of 57mol/L, white
blood cell count of 15.6k/L, hemoglobin of 9.6g/dL,
platelets of 174k/L, and a urinalysis with 3+ protein.
Her chest X-ray showed mild pulmonary vascular
congestion. A right upper quadrant ultrasound showed
decreased flow in hepatic vein and mild ascites. Her
MRI/MRA/MRV of the abdomen showed narrowing of
hepatic vein and inferior vena cava (IVC). The renal
ultrasound showed no hydronephrosis.
Discussion
This case allows the discussion of liver disease during
pregnancy, however the focus of this discussion will be
on the Budd-Chiari Syndrome (BCS).
Pathogenesis
The patient in this case had signs and symptoms
consistent with BCS or hepatic venous outflow
obstruction. BCS describes a group of disorders that cause
outflow obstruction at the level of the hepatic venule,
large hepatic veins, inferior vena cava or right atrium.
Hepatic veno-occlusive disease refers to obstruction at the
level of the center of sub-lobular hepatic veins. Hepatic
venous outflow tract obstruction results in increased
sinusoidal pressure and portal hypertension. Early in the
disease, portal venous perfusion is diminished which may
result in portal vein thrombosis. Venous stasis leads to
centrolobular necrosis, fibrosis and eventually cirrhosis. If
a portosystemic shunt is created or portal venous
collaterals develop, liver function improves by reducing
sinusoidal pressure. About 75% of patients have an
identifiable cause of BCS. Hereditary and acquired
hypercoagulable states are a common cause.
Myeloproliferative disorders are the most common cause
of BCS, most notably polycythemia vera. Other causes
include paroxysmal nocturnal hemoglobinuria, antiphospholipid syndrome, inherited deficiencies of proteins C
and S and antithrombin III. BCS has been described in
pregnancy and the immediate post-partum period.
Clinical Manifestations
BCS can be grouped into fulminant, acute, subacute and
chronic depending on the speed which the hepatic veins
become occluded and whether collateral circulation
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exists. Abdominal pain, hepatomegaly and ascites are the
most common findings. Nausea, vomiting and jaundice
are more common in the fulminant and acute forms.
Splenomegaly and esophageal varices are more common
in the chronic forms. IVC occlusion usually causes
dilated venous collaterals on the back and flanks. Patients
with acute BCS have ascites, hepatic necrosis, symptoms
of short duration and lack of venous collaterals. Hepatic
necrosis and ascites are usually minimal in the subacute
form because venous collaterals have decompressed the
hepatic sinusoids. The subacute form is the most
common form of BCS. A careful cardiovascular
examination can separate BCS from cardiac causes of
diminished hepatic venous outflow. Right atrial myxoma,
tricuspid regurgitation and constrictive pericarditis can
cause similar symptoms to BCS. Lack of hepatojugular
reflux is indicative of BCS on physical examination.
Diagnosis
Laboratory evaluation shows AST and ALT to be five
times the upper limit of normal in fulminant and acute
forms of BCS. The subacute form has lower values.
Alkaline phosphatase and bilirubin levels are also
elevated. Serum-ascitic fluid albumin gradient is high.
Doppler ultrasound is the diagnostic imaging of choice
with a sensitivity and specificity of 85%. MRI can show
hepatic vein thrombosis and may be better for
delineating acute from subacute and chronic forms.
Hepatic venography is used as a confirmatory test when
ultrasound is negative but there is a strong clinical
suspicion. The classic “spiderweb” pattern is often seen.
The patient in this case had an MRI which showed
narrowing of the hepatic vein and IVC which is
consistent with BCS.
Management
Medical management focuses on treating the underlying
cause, anticoagulation to prevent extension of
thrombosis and efforts to reduce ascites. Diuretics such
as furosemide and spironolactone as well as paracentesis
and sodium restriction are used to reduce ascites.
Heparin is used initially with conversion to warfarin with
a goal INR of 2.0 to 2.5. Medical management is
generally recommended for patients with few symptoms,
no hepatic necrosis and minimal ascites. Patients with
coagulopathy, encephalopathy and hepatorenal
syndrome have a poor prognosis and require immediate
relief of hepatic venous obstruction.

Thrombolytics can be used in the acute form of BCS
particularly when an acute thrombus is seen on
angiography. TPA or urokinase is directly infused by
catheter for 24 hours. The overall success rate is low with
thrombolytics, but positive results have occurred as far
as two to three weeks after onset of symptoms.
Percutaneous or transhepatic angioplasty of segments of
the narrowed hepatic vein can also be performed.
Symptom relief occurs in up to 70% of patients, but
restenosis rates are high.
Transjugular intrahepatic portosystemic shunts (TIPS)
are typically used in patients who have an occluded IVC
when the portal vein-infrahepatic vena caval pressure
gradient is less than 10mm Hg and when there is poor
hepatic reserve. TIPS can also be used in acute BCS after
failure of thrombolytic therapy. TIPS can be used as a
bridge to liver transplantation. Even if the shunt
occludes, it may allow enough time for collaterals to
develop and decrease sinusoidal pressure.
Surgical options include excision of IVC webs followed by
angioplasty of the vena cava, although portosystemic
shunting and liver transplantation are the most common
surgical treatments for BCS. Surgical portosystemic shunts
are recommended in subacute forms of BCS when the
underlying etiology has a favorable outcome, the patient is
a good surgical candidate and when liver biopsy shows
ongoing hepatic necrosis. A portal vein and IVC pressure
gradient of more than 10 mm Hg is associated with a
successful long-term outcome. Examples of surgical shunts
include side-to-side portocaval shunt, central splenorenal
shunt, and a mesocaval shunt. The five-year survival rate
after surgical shunting is between 75% and 94%.
The five-year survival rate for liver transplantation in
patients with BCS is 95%. Indications are an underlying
disease associated with a favorable prognosis, fulminant
hepatic failure, cirrhosis, and failure of portosystemic
shunt. Not all patients require long-term anticoagulant
therapy after liver transplantation, but it may be
reasonable to anticoagulate since patients with BCS have
multiple underlying etiologic factors.
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